NDATOPICALOINTMENT
Approved
Dec 2016
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
15
Data completeness
7/8 — Comprehensive
EUCRISA (crisaborole) by R-Pharm US is phosphodiesterase 4 inhibitors [moa]. Approved for atopic dermatitis, eczema. First approved in 2016.
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
EUCRISA (crisaborole) is a topical phosphodiesterase 4 inhibitor ointment approved in December 2016 for atopic dermatitis. It represents a non-corticosteroid, non-calcineurin inhibitor option for treating inflammatory skin conditions. The drug works by inhibiting phosphodiesterase 4 enzymes, reducing inflammatory mediator production in affected skin. It occupies a middle position in the atopic dermatitis treatment landscape, positioned between topical corticosteroids and systemic biologic therapies.
$0.0BPart D
4.2 years to LOEMechanism of Action
Phosphodiesterase 4 Inhibitors
Pharmacologic Class:
Phosphodiesterase 4 Inhibitor
Indications (2)
Clinical Trials (15)
Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo
Started Sep 2022
32 enrolled
Vitiligo
A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis
Started Sep 2020
40 enrolled
Atopic Dermatitis
Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis
Started Jul 2020
391 enrolled
Atopic Dermatitis
Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis
Started Jun 2020
66 enrolled
Stasis Dermatitis
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Started Feb 2020
150 enrolled
Atopic Dermatitis
Worked on EUCRISA at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.